Why AbbVie Inc. Slumped 13% In September
-
Upload
the-motley-fool -
Category
Healthcare
-
view
7.469 -
download
2
Transcript of Why AbbVie Inc. Slumped 13% In September
![Page 1: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/1.jpg)
Why Abbvie Inc. Slumped 13% In September
![Page 2: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/2.jpg)
What:• The large cap biopharma company is investing heavily in R&D to
offset risk tied to the looming patent expiration of Humira.– Humira generates more than $12 billion in annual sales.– Humira accounts for 63% of year-to-date revenue.
• Expansion into hepatitis C offers billion dollar potential.– Competitor Gilead Sciences reports positive phase 3 data for its
pan-genotype hepatitis C drug on September 21.• Shares dropped 12.8% in September.
Source Juno Therapeutics
![Page 3: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/3.jpg)
AbbVie Inc.
![Page 4: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/4.jpg)
So what:• Humira is AbbVie’s top selling therapy.– Sales of $6.6 billion through the first six months of 2015.– Patent protection ends on Humira in 2016.
• AbbVie launched Viekira Pak for hepatitis C in Q1 2015– Viekira Pak Q2 sales tracking at an annualized $1.5 billion
pace.
![Page 5: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/5.jpg)
So what continued:
![Page 6: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/6.jpg)
So what continued:• Gilead Sciences announces positive data for next-generation, pan-genotype
hepatitis C therapy.– 99% overall cure rate, including 98% rate in genotype 1.
• Could reduce demand for Viekira Pak in genotype 1 patients.– Robust efficacy across genotypes 1 to 6.
• Could remove need for genotype testing.• Could outmaneuver AbbVie’s pan-genotype next generation therapy:
ABT-493 + ABT-530.
![Page 7: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/7.jpg)
Now what:• Humira patent risk looms, but efforts underway on next-generation
autoimmune drugs.• ABT-494: Advancing into late stage trials by year end.
– 82% of rheumatoid arthritis patients achieved a 20% or greater improvement in symptoms in phase 2 trials.
– In anti-TNF (such as Humira) non-responders, 71% achieved a 20% or greater improvement.
– Safety profile potentially better than Humira with most common adverse event being headache.
– Oral dosing rather than injection dosing like Humira.
![Page 8: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/8.jpg)
Now what continued:• Significant opportunity in oncology.– Acquired Pharmacyclics in May to get Imbruvica.• Fast growing drug with billion dollar annual sales potential.
– Venetoclax potential regulatory filing by year end.• Relapsed/refractory CLL with 17p deletion genetic mutation.
– Elotuzumab filed for approval. • Decision expected in February 2016.• Improved progression free survival when added to standard
of care.
![Page 9: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/9.jpg)
Now what continued:• Absent a Humira successor, significant risk remains.• Continue to monitor progress on oncology pipeline.• Look for insight into timeline for next-generation pan-
genotype HCV therapies during Q3 EPS report.• Recent decline may offer opportunity if company can
execute on its plan to overcome Humira risk.– Underweight in portfolios until clarity exists.
![Page 10: Why AbbVie Inc. Slumped 13% In September](https://reader033.fdocuments.in/reader033/viewer/2022042907/587379181a28ab3c1a8b6e5b/html5/thumbnails/10.jpg)
Leaked: The next billion-dollar iSecret